Modern Health Welcomes New Chief Technology Officer and General Counsel
New Data from Modern Health Reinforces Proven Model and Offers Fresh Insight into Evolving Workforce Needs
Article content
SAN FRANCISCO — Modern Health, a leading global workplace mental health platform, today announced the appointments of Chen Cheng as Chief Technology Officer and Erin Brown as General Counsel, along with other company momentum, as it accelerates its mission to make mental health care more accessible, personalized, and effective worldwide.
Article content
In her role as Chief Technology Officer, Chen Cheng will oversee the company's technology and further scale the platform to provide high-quality, clinically rigorous care across the globe. She brings more than a decade of experience in the health technology sector to Modern Health, including roles at Oscar Health and ZocDoc. As technology plays an increasingly critical role in expanding access to mental health care and support, evidenced by the growing engagement with virtual therapy, coaching, and digital tools, Chen will leverage her tech experience and leadership to help Modern Health advance its innovations.
Article content
Erin Brown joins Modern Health as General Counsel, bringing more than 20 years of legal experience across the health and benefits space. Brown has amassed a proven track record of guiding high-growth organizations through complex legal and regulatory environments. Prior to Modern Health, Brown was Senior Vice President and Associate General Counsel at Alight Solutions and, before that, Associate General Counsel at Aon Hewitt. Her expertise and strategic counsel will be key as Modern Health continues to expand its global footprint and innovate responsibly in a rapidly evolving industry.
Article content
'Welcoming exceptional leaders like Chen and Erin marks an exciting step forward for Modern Health,' said Matt Levin, CEO of Modern Health. 'They each bring a powerful combination of industry expertise and a passion for making mental health care more accessible, personalized, and effective. Their leadership will accelerate our momentum as we scale our impact, drive innovation, and continue delivering meaningful outcomes for the workplaces we support worldwide.'
Article content
In addition to these appointments, other recent company momentum includes:
Article content
Modern Health has been named to the 2025 Inc. 5000 list of the fastest-growing private companies in America. The list highlights companies that have demonstrated significant revenue growth over a three-year period and serves as a benchmark for entrepreneurial success and a platform for recognizing the contributions of these businesses to the US economy.
Modern Health launches ROI Study that proves mental health care pays off: According to a third-party analysis of 13,000+ members, the most significant savings (60% of total savings) in health care spend for employers come from reaching more employees earlier with support that fits their needs before symptoms escalate. Modern Health's evidence-based Adaptive Care Model delivers an estimated $2.39 return for every dollar invested, based solely on health care cost savings. These compelling findings underscore how Modern Health's Adaptive Care Model improves outcomes and drives down costs by supporting the whole workforce—not just those with severe mental health concerns.
Peer-reviewed data shows Modern Health's global mental health model works anywhere: In one of the largest and most diverse real-world studies of its kind, Modern Health examined engagement and clinical outcomes among more than 33,000 members across seven global regions to understand not only how mental health needs vary across regions but also whether a single care model could truly work at a global scale. The study proves that achieving global scale requires more than a one-size-fits-all approach; it demands an adaptive, evidence-based model designed to deliver meaningful results across diverse regions and populations.
Modern Health's latest study paints a stark picture of how Gen Z and Millennial employees are faring: In a study of 1,000 American professionals aged 18 to 44, the findings reveal a generation silently struggling under the weight of burnout, financial anxiety, and workplace systems that haven't kept pace with their needs. Among the most striking statistics: 75% blame financial stress for fueling burnout and hurting productivity, 79% sacrifice mental health to meet work demands, and 96% want access to preventative mental health support. The workplace report highlights a troubling reality: too many young workers are quietly pushing through mounting mental health challenges just to keep up at work, underscoring the urgent need to meet people earlier, with care that's proactive, adaptive, and designed to support the mental health of entire workforce populations.
Launch of FlexEAP Challenges Outdated Employee Assistance Programs: Modern Health recently launched FlexEAP ('Flex'), a next-gen Employee Assistance Program (EAP) addressing the critical shortcomings of traditional EAPs by delivering rapid access to care, adaptive support extending far beyond crisis intervention, and a seamless, consistent global experience. The product combines Modern Health's Adaptive Care Model with an elite, global provider network to deliver a seamless, personalized mental health experience. Employees can access care, on average, within 24 hours, with fast, frictionless support across therapy, coaching, crisis intervention, and digital self-guided tools. Flex delivers superior outcomes and an upgraded, consumer-grade experience compared to traditional EAPs, while offering flexible pricing, customizable solutions, and risk-sharing based on utilization—empowering employers to better manage costs.
Expanded Languages for Pathways: Modern Health is proud to offer its Pathways Collections, offering tailored one-on-one support around a variety of topics, including Workplace Well-being, Family Care, and Physical Well-Being, as a truly multilingual product. Now, members can connect with a Pathway Provider in six additional languages — Spanish, Dutch, Hindi, Portuguese, Japanese, and French.
Article content
About Modern Health
Article content
Modern Health is a global leader in adaptive mental health care, dynamically offering multi-modal mental health support that delivers meaningful outcomes at a sustainable, predictable cost. With therapy, psychiatry, coaching, community groups, self-guided tools, and crisis support, we dynamically create individualized care journeys to address a spectrum of mental health needs and preferences with culturally responsive providers in 200+ countries and territories and 80+ languages. Backed by peer-reviewed research and a proprietary blend of technology and live support, Modern Health delivers measurable outcomes, globally equitable access, and sustainable pricing. Our industry-leading Adaptive Care Model and dedicated, human centered, operationally tuned, customer success partners make us a trusted partner for organizations worldwide.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Union says 'nothing scheduled' with Air Canada as strike by flight attendants halts operations
Social Sharing The union representing Air Canada flight attendants says no talks are scheduled with the airline as a strike that began early Saturday led to the airline suspending operations. The union and airline met late Friday night before 10,000 flight attendants walked off the job at 12:58 a.m. ET, Wesley Lesosky, president of the Air Canada component of the Canadian Union of Public Employees (CUPE), told a morning news conference. Lesosky said their last meeting was Friday night, but Air Canada offered "nothing of substance" to bring back to members. Asked when Canadians could expect to be back on flights, Lesosky said it's up to Air Canada, but that public pressure on the airline will make a "huge difference" in reaching a settlement. CBC News has reached out to Air Canada for comment and will update this story with any response. Jobs Minister Patty Hajdu also met with both the airline and union on Friday night. "It is unacceptable that such little progress has been made. Canadians are counting on both parties to put forward their best efforts," Hajdu said on social media platform X. Picket lines set up across Canada All Air Canada and Air Canada Rouge flights are suspended for now. Around 130,000 customers will be affected each day the strike continues, said the airline. Flights by Air Canada Express, which are operated by third-party airlines Jazz and PAL, are not affected. Cross Country Checkup is asking: How have you been affected by the Air Canada strike? What should be done about it? Leave your comment here and we may read it or call you back for our show on Sunday. "Air Canada deeply regrets the effect the strike is having on customers," it said in a brief statement early Saturday morning. CUPE has set up picket lines at airports across Canada, including in Montreal, Toronto, Calgary and Vancouver. Striking flight attendants also plan to picket at airports in Halifax, Ottawa and Winnipeg. In the meantime, passengers around the world are feeling the effects of the flight attendants' strike. Keelin Pringnitz and her family are from Ottawa and were returning from a European vacation, but were left stranded after flights were cancelled. "It was an end of my maternity leave kind of trip. We went to the Faroe Islands and Norway, travelling through Air Canada to London," Pringnitz said from London's Heathrow Airport. She noted there was an option for travellers to go the U.S. but she and others were told there wouldn't be any further assistance once they landed in the U.S. "It didn't go over well with the line. Nobody really seemed interested, everybody seemed a little bit amused almost at the suggestion, or exasperated, because it is a bit ridiculous to offer to take stranded passengers to a different country to strand them there." For customers due to travel soon whose flights are not yet cancelled, Air Canada said it will allow them to rebook their travel or obtain a credit for future travel. Sides at an impasse on pay Air Canada and CUPE have been in contract talks for about eight months, but have yet to reach a tentative deal. Both sides say they remain far apart on the issue of pay and the unpaid work flight attendants do when planes aren't in the air. WATCH | Thousands of Air Canada flight attendants walk off the job: Air Canada strike begins as flight attendants walk off the job 2 hours ago More than 10,000 Air Canada flight attendants went on strike early Saturday morning, after the airline and the union representing them failed to reach a deal ahead of the deadline. With a work stoppage now in effect, Air Canada estimates that 130,000 customers will be affected each day of a strike, a figure that includes 25,000 Canadian travellers who are abroad. The airline's latest offer included a 38 per cent increase in total compensation, including benefits and pensions over four years, that it said "would have made our flight attendants the best compensated in Canada." But the union pushed back, saying the proposed 8 per cent raise in the first year didn't go far enough because of inflation. Government intervention Air Canada previously asked Hajdu to intervene by ordering the parties to enter a binding arbitration process — a power granted to the minister through Sec. 107 of the Canada Labour Code. On Friday, Hajdu urged Air Canada and the union to get back to the negotiating table, suggesting she's not ready to intervene. The minister said the union has indicated many of its demands have been met, suggesting there is a path forward to a deal. WATCH | The impact of the flight attendants' strike on travellers: Air Canada flight attendants strike, setting stage for travel chaos 10 hours ago Canada's largest airline is now mostly grounded after a strike deadline passed for more than 10,000 Air Canada flight attendants. Hundreds of flights have been cancelled impacting over 100,000 travellers and leaving some stranded. Hajdu had asked the union to respond to the company's request. CUPE indicated Friday it opposed arbitration, instead maintaining its desire to solve the impasse through bargaining.
Globe and Mail
an hour ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
2 hours ago
- Globe and Mail
WKHS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Workhorse Group Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Workhorse Group Inc. (NASDAQ: WKHS) and Motiv Electric Trucks is fair to Workhorse shareholders. Upon completion of the proposed transaction, Workhorse shareholders will own approximately 26.5% of the combined company. Halper Sadeh encourages Workhorse shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether Workhorse and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Workhorse shareholders; and (2) disclose all material information necessary for Workhorse shareholders to adequately assess and value the merger consideration. On behalf of Workhorse shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
